SG186219A1 - Direct cloning - Google Patents
Direct cloning Download PDFInfo
- Publication number
- SG186219A1 SG186219A1 SG2012090056A SG2012090056A SG186219A1 SG 186219 A1 SG186219 A1 SG 186219A1 SG 2012090056 A SG2012090056 A SG 2012090056A SG 2012090056 A SG2012090056 A SG 2012090056A SG 186219 A1 SG186219 A1 SG 186219A1
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acid
- acid molecule
- rece
- linear
- homologous recombination
- Prior art date
Links
- 238000010367 cloning Methods 0.000 title claims description 68
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 323
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 317
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 317
- 238000000034 method Methods 0.000 claims abstract description 210
- 238000002744 homologous recombination Methods 0.000 claims abstract description 130
- 230000006801 homologous recombination Effects 0.000 claims abstract description 130
- 108020004414 DNA Proteins 0.000 claims description 186
- 108090000623 proteins and genes Proteins 0.000 claims description 133
- 210000004027 cell Anatomy 0.000 claims description 128
- 239000013598 vector Substances 0.000 claims description 87
- 108091034117 Oligonucleotide Proteins 0.000 claims description 76
- 108010068698 spleen exonuclease Proteins 0.000 claims description 67
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 230000014509 gene expression Effects 0.000 claims description 60
- 230000001404 mediated effect Effects 0.000 claims description 56
- 150000001413 amino acids Chemical class 0.000 claims description 49
- 238000001727 in vivo Methods 0.000 claims description 49
- 101100226347 Escherichia phage lambda exo gene Proteins 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 46
- 125000003729 nucleotide group Chemical group 0.000 claims description 44
- 102000004190 Enzymes Human genes 0.000 claims description 42
- 108090000790 Enzymes Proteins 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 42
- 101100316841 Escherichia phage lambda bet gene Proteins 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 40
- 238000000137 annealing Methods 0.000 claims description 38
- 239000013599 cloning vector Substances 0.000 claims description 38
- 238000005520 cutting process Methods 0.000 claims description 38
- 239000002299 complementary DNA Substances 0.000 claims description 36
- 230000001939 inductive effect Effects 0.000 claims description 33
- 108010055016 Rec A Recombinases Proteins 0.000 claims description 29
- 102000001218 Rec A Recombinases Human genes 0.000 claims description 29
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 26
- 210000000349 chromosome Anatomy 0.000 claims description 24
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 21
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 19
- 238000004520 electroporation Methods 0.000 claims description 18
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 17
- 108091008053 gene clusters Proteins 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 101150061231 recE gene Proteins 0.000 claims description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 7
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 6
- 229930000044 secondary metabolite Natural products 0.000 claims description 6
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000004136 fatty acid synthesis Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 238000005215 recombination Methods 0.000 description 109
- 230000006798 recombination Effects 0.000 description 106
- 239000013612 plasmid Substances 0.000 description 67
- 239000000047 product Substances 0.000 description 61
- 241000588724 Escherichia coli Species 0.000 description 48
- 102000053602 DNA Human genes 0.000 description 33
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 26
- 101150038013 PIR gene Proteins 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 108020004682 Single-Stranded DNA Proteins 0.000 description 22
- 230000006698 induction Effects 0.000 description 21
- 239000003550 marker Substances 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 230000009466 transformation Effects 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 16
- 229930027917 kanamycin Natural products 0.000 description 16
- 229960000318 kanamycin Drugs 0.000 description 16
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 16
- 229930182823 kanamycin A Natural products 0.000 description 16
- 238000007792 addition Methods 0.000 description 15
- 239000013613 expression plasmid Substances 0.000 description 15
- 230000010076 replication Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 12
- 241001646716 Escherichia coli K-12 Species 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 101150102092 ccdB gene Proteins 0.000 description 10
- 108060002716 Exonuclease Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 102000013165 exonuclease Human genes 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229960005091 chloramphenicol Drugs 0.000 description 8
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 108010091086 Recombinases Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 6
- 102000018120 Recombinases Human genes 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 101150079601 recA gene Proteins 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 102100031780 Endonuclease Human genes 0.000 description 5
- 241001148064 Photorhabdus luminescens Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000010474 transient expression Effects 0.000 description 5
- 101100355997 Bacillus subtilis (strain 168) recA gene Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101100301301 Escherichia coli (strain K12) recE gene Proteins 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 101100386214 Bacillus subtilis (strain 168) dabA gene Proteins 0.000 description 3
- 101100012155 Escherichia coli (strain K12) exoD gene Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229930189065 blasticidin Natural products 0.000 description 3
- 210000004900 c-terminal fragment Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000008519 endogenous mechanism Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 101150022010 gam gene Proteins 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 101100356230 Escherichia coli (strain K12) recT gene Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101150003028 Hprt1 gene Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 101100365003 Mus musculus Scel gene Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 101150023497 mcrA gene Proteins 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101150024821 tetO gene Proteins 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000428352 Amma Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100402795 Caenorhabditis elegans mtl-1 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010046914 Exodeoxyribonuclease V Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001523412 Heterorhabditis bacteriophora Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101100301239 Myxococcus xanthus recA1 gene Proteins 0.000 description 1
- 101150109417 NRPS gene Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101100205180 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-6 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001307210 Pene Species 0.000 description 1
- 241001148062 Photorhabdus Species 0.000 description 1
- 108010019477 S-adenosyl-L-methionine-dependent N-methyltransferase Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108091007416 X-inactive specific transcript Proteins 0.000 description 1
- 108091035715 XIST (gene) Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 101150043283 ccdA gene Proteins 0.000 description 1
- 238000011259 co-electroporation Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 101150106284 deoR gene Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000967 entomopathogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 101150045500 galK gene Proteins 0.000 description 1
- 101150041954 galU gene Proteins 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 101150096208 gtaB gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108700010833 lambda phage proteins Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- -1 merBC Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 108010000785 non-ribosomal peptide synthase Proteins 0.000 description 1
- 101150012154 nupG gene Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 101150059159 proA2 gene Proteins 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 101150087770 recT gene Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- 101150047315 sbcC gene Proteins 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/16—Exonucleases active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters (3.16)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1009732.7A GB201009732D0 (en) | 2010-06-10 | 2010-06-10 | Direct cloning |
| PCT/IB2011/052549 WO2011154927A2 (en) | 2010-06-10 | 2011-06-10 | Direct cloning |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG186219A1 true SG186219A1 (en) | 2013-01-30 |
Family
ID=42471456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012090056A SG186219A1 (en) | 2010-06-10 | 2011-06-10 | Direct cloning |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10443051B2 (enExample) |
| EP (2) | EP3138921A1 (enExample) |
| JP (2) | JP5934196B2 (enExample) |
| CN (2) | CN103068995B (enExample) |
| CA (1) | CA2802167C (enExample) |
| GB (1) | GB201009732D0 (enExample) |
| SG (1) | SG186219A1 (enExample) |
| WO (1) | WO2011154927A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201009732D0 (en) | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| EP2612918A1 (en) * | 2012-01-06 | 2013-07-10 | BASF Plant Science Company GmbH | In planta recombination |
| CN102558309B (zh) * | 2012-02-10 | 2014-09-17 | 浙江大学 | 一对转录激活子样效应因子核酸酶及其编码基因与应用 |
| CN102627691B (zh) * | 2012-04-05 | 2014-09-17 | 浙江大学 | 一对转录激活子样效应因子核酸酶及其编码基因与应用 |
| JP6275120B2 (ja) * | 2012-04-25 | 2018-02-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 大きい標的化ベクターによるヌクレアーゼ媒介標的化 |
| CN102702335B (zh) * | 2012-05-23 | 2014-07-09 | 上海斯丹赛生物技术有限公司 | 重组转录激活子样效应因子、转录激活子样效应因子核酸酶及其编码基因及应用 |
| US20150267210A1 (en) | 2012-10-16 | 2015-09-24 | Genebridges Gmbh | Electrocompetent cells and preparation thereof |
| EP3456831B1 (en) | 2013-04-16 | 2021-07-14 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
| MX388127B (es) | 2013-12-11 | 2025-03-19 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| AU2014368982B2 (en) * | 2013-12-19 | 2021-03-25 | Amyris, Inc. | Methods for genomic integration |
| BR112016028564A2 (pt) | 2014-06-06 | 2018-01-30 | Regeneron Pharma | método para modificar um locus-alvo em uma célula. |
| MX384887B (es) | 2014-06-23 | 2025-03-14 | Regeneron Pharma | Ensamblaje de adn mediado por nucleasa. |
| SG10201911411YA (en) | 2014-06-26 | 2020-02-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
| CA3176380A1 (en) | 2014-11-21 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| CN105713885B (zh) * | 2014-12-04 | 2019-06-11 | 清华大学 | 特异识别并修复β地中海贫血症beta-globin基因的嵌合核酸酶 |
| BR112017013104A2 (pt) * | 2014-12-19 | 2018-05-15 | Regeneron Pharma | métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano. |
| CN105734061B (zh) * | 2016-03-25 | 2019-07-23 | 中国农业科学院生物技术研究所 | 从毕赤酵母中分离的鼠李糖诱导型启动子及其应用 |
| CN109715813A (zh) * | 2016-04-06 | 2019-05-03 | 基因桥有限公司 | 腺病毒载体 |
| CN106995813B (zh) * | 2017-03-23 | 2020-06-16 | 山东大学 | 基因组大片段直接克隆和dna多分子组装新技术 |
| CN109385417A (zh) * | 2017-08-03 | 2019-02-26 | 华东理工大学 | 体内dna无缝组装方法 |
| MX2021012158A (es) * | 2019-04-05 | 2022-01-06 | Danisco Us Inc | Métodos para la integración de una secuencia de adn donante en el genoma de bacillus usando constructos de adn recombinante lineal y composiciones de los mismos. |
| CN110184287B (zh) * | 2019-05-24 | 2024-01-30 | 华南农业大学 | 一种制备重组病毒的方法及其应用 |
| CN114630910A (zh) | 2019-06-25 | 2022-06-14 | 伊纳瑞农业技术有限公司 | 改善的同源依赖修复基因组编辑 |
| CN115717152A (zh) * | 2022-11-29 | 2023-02-28 | 江南大学 | 一种控制枯草芽孢杆菌基因组同源重组概率的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043272A (en) | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
| US5776744A (en) * | 1995-06-07 | 1998-07-07 | Yale University | Methods and compositions for effecting homologous recombination |
| ATE449844T1 (de) | 1997-12-05 | 2009-12-15 | Europ Lab Molekularbiolog | Neue methode zur klonierung dns unter anwendung des e. coli rece/rect rekombinationssystems |
| AUPP684998A0 (en) * | 1998-10-30 | 1998-11-26 | Murdoch Institute for Research into Birth Defects Limited, The | A method of recombination and agents useful for same |
| US6355412B1 (en) * | 1999-07-09 | 2002-03-12 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
| US6569681B1 (en) * | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| EP1399546A2 (en) | 2001-02-09 | 2004-03-24 | Gene Bridges GmbH | Recombination method |
| WO2003010322A1 (en) * | 2001-07-20 | 2003-02-06 | Youming Zhang | Improved rect or recet cloning and subcloning method |
| EP1590468A2 (en) * | 2003-01-28 | 2005-11-02 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| WO2007013979A2 (en) | 2005-07-20 | 2007-02-01 | Invitrogen Corporation | Methods for increasing efficiency of homologous recombination |
| KR100681815B1 (ko) * | 2005-12-02 | 2007-02-12 | 한국생명공학연구원 | 리컴비네이즈 매개 선택표지 유전자 발현유도에 의한 목표유전자 간편 클로닝 및 목표 단백질 신속 발현 방법. |
| EP2027313B1 (en) * | 2006-03-27 | 2012-05-16 | Children's Hospital & Regional Medical Center | Compositions and methods comprising the use of cell surface displayed homing endonucleases |
| GB0803109D0 (en) * | 2008-02-20 | 2008-03-26 | Gene Bridges Gmbh | Method of nucleic acid recombination |
| JP2011217736A (ja) * | 2010-03-26 | 2011-11-04 | Aichi Medical Univ | 組換えクラミジア及びその製造方法 |
| GB201009732D0 (en) * | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
-
2010
- 2010-06-10 GB GBGB1009732.7A patent/GB201009732D0/en not_active Ceased
-
2011
- 2011-06-10 JP JP2013513806A patent/JP5934196B2/ja active Active
- 2011-06-10 EP EP16192084.8A patent/EP3138921A1/en not_active Withdrawn
- 2011-06-10 EP EP11729474.4A patent/EP2580338B1/en active Active
- 2011-06-10 CA CA2802167A patent/CA2802167C/en active Active
- 2011-06-10 CN CN201180038908.6A patent/CN103068995B/zh active Active
- 2011-06-10 CN CN201810875866.5A patent/CN109825486A/zh active Pending
- 2011-06-10 US US13/806,086 patent/US10443051B2/en active Active
- 2011-06-10 WO PCT/IB2011/052549 patent/WO2011154927A2/en not_active Ceased
- 2011-06-10 SG SG2012090056A patent/SG186219A1/en unknown
-
2016
- 2016-05-06 JP JP2016093169A patent/JP2016135158A/ja active Pending
-
2019
- 2019-09-06 US US16/563,274 patent/US12195732B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20130210681A1 (en) | 2013-08-15 |
| JP2013530689A (ja) | 2013-08-01 |
| WO2011154927A9 (en) | 2013-01-24 |
| US12195732B2 (en) | 2025-01-14 |
| CN103068995A (zh) | 2013-04-24 |
| WO2011154927A3 (en) | 2012-02-16 |
| JP5934196B2 (ja) | 2016-06-15 |
| CN109825486A (zh) | 2019-05-31 |
| JP2016135158A (ja) | 2016-07-28 |
| CA2802167C (en) | 2023-03-07 |
| US20200283759A1 (en) | 2020-09-10 |
| GB201009732D0 (en) | 2010-07-21 |
| WO2011154927A2 (en) | 2011-12-15 |
| EP3138921A1 (en) | 2017-03-08 |
| CN103068995B (zh) | 2020-10-16 |
| EP2580338B1 (en) | 2016-10-05 |
| CA2802167A1 (en) | 2011-12-15 |
| US10443051B2 (en) | 2019-10-15 |
| EP2580338A2 (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12195732B2 (en) | Direct cloning | |
| US10287590B2 (en) | Methods for generating libraries with co-varying regions of polynuleotides for genome modification | |
| Akhmetov et al. | Single-step precision genome editing in yeast using CRISPR-Cas9 | |
| CN106995813B (zh) | 基因组大片段直接克隆和dna多分子组装新技术 | |
| EP1291420B1 (en) | Novel DNA cloning method relying on the E.coli RECE/RECT recombination system | |
| EP2255001B1 (en) | Method of nucleic acid recombination | |
| Muyrers et al. | ET-cloning: think recombination first | |
| US20230183678A1 (en) | In-cell continuous target-gene evolution, screening and selection | |
| US20250243514A1 (en) | Compositions, methods, and systems for dna modification | |
| JP2004535773A (ja) | 組換え法 | |
| WO2010113031A2 (en) | Method of altering nucleic acids | |
| US20240052370A1 (en) | Modulating cellular repair mechanisms for genomic editing | |
| WO2010140066A2 (en) | Method of altering nucleic acids | |
| EP1012314A1 (en) | A vector and method for preparation of dna libraries |